Skip to main content

Advertisement

Log in

Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Neuroendocrine tumors (NETs) are rare tumors that have been increasing in incidence over the last 30 years with no significant changes in survival. As survival of patients with these tumors depends greatly on stage and histology, early diagnosis, classification and staging of tumors in patients in whom NETs are suspected are of great importance. Surgery, either with curative or palliative intent, is the mainstay of treatment for localized NETs. Therapeutic options for this disease almost invariably include somatostatin analogs to alleviate the symptoms of excessive hormone secretion. Other approaches for advanced disease may include hepatic artery embolization or ablation, peptide receptor radionuclide therapy and systemic chemotherapy. Recent advances regarding the signaling pathways involved in tumor development have allowed the development of novel targeted therapies. However, due to the lack of prognostic molecular markers to identify high-risk patients and the absence of a common pathogenesis in all patients, treatment selection is often empirical. There is therefore a need to establish a consensus for the treatment of this disease and to provide evidence-based clinical recommendations and algorithms to optimize and individualize the treatment and follow-up for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Fave GD, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72. doi:10.1016/S1470-2045(07)70410-2

    Article  CAS  PubMed  Google Scholar 

  2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072. doi:10.1200/JCO.2007.15.4377

    Article  PubMed  Google Scholar 

  3. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959. doi:10.1002/cncr.11105

    Article  PubMed  Google Scholar 

  4. Oberg K (2005) Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET’s). Rocz Akad Med Bialymst 50:62–68

    CAS  PubMed  Google Scholar 

  5. Oberg K (1999) Neuroendocrine gastrointestinal tumors—a condensed overview of diagnosis and treatment. Ann Oncol 10(Suppl 2):S3–S8

    Article  PubMed  Google Scholar 

  6. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793. doi:10.1007/s00259-003-1184-3

    Article  CAS  PubMed  Google Scholar 

  7. Mansour JC, Chen H (2004) Pancreatic endocrine tumors. J Surg Res 120:139–161. doi:10.1016/j.jss.2003.12.007

    Article  CAS  PubMed  Google Scholar 

  8. Kloppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13–27

    Article  PubMed  Google Scholar 

  9. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401. doi:10.1007/s00428-006-0250-1

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762. doi:10.1007/s00428-007-0452-1

    Article  CAS  PubMed  Google Scholar 

  11. Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK (2013) Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 31:420–425. doi:10.1200/JCO.2012.44.5924

    Article  PubMed  Google Scholar 

  12. Oxford centre for evidence-based medicine. Levels of evidence. http://www.cebm.net/?o=1025. Accessed 8th October 2012

  13. Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP (2010) Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139:742–753, 753 e741. doi:10.1053/j.gastro.2010.07.002

  14. Karashima T, Cai RZ, Schally AV (1987) Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sci 41:1011–1019

    Article  CAS  PubMed  Google Scholar 

  15. Hoyer D, Lubbert H, Bruns C (1994) Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 350:441–453

    Article  CAS  PubMed  Google Scholar 

  16. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G (1996) Binding properties of somatostatin receptor subtypes. Metabolism 45:17–20

    Article  CAS  PubMed  Google Scholar 

  17. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: a very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci 31:1133–1140

    Article  CAS  PubMed  Google Scholar 

  18. Murphy WA, Lance VA, Moreau S, Moreau JP, Coy DH (1987) Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci 40:2515–2522

    Article  CAS  PubMed  Google Scholar 

  19. Reubi JC, Schonbrunn A (2013) Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 34:676–688. doi:10.1016/j.tips.2013.10.001

    Article  CAS  PubMed  Google Scholar 

  20. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ (1996) Somatostatin analog octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38:430–438

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, Kelsen D (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72:244–248

    Article  CAS  PubMed  Google Scholar 

  22. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663. doi:10.1200/JCO.2009.22.8510

    Article  CAS  PubMed  Google Scholar 

  23. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276–3281. doi:10.1111/j.1572-0241.2000.03210.x

    Article  CAS  PubMed  Google Scholar 

  24. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG, Oberg KE (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17:1111

    CAS  PubMed  Google Scholar 

  25. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233. doi:10.1056/NEJMoa1316158

    Article  PubMed  Google Scholar 

  26. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707–716

    Article  CAS  PubMed  Google Scholar 

  27. Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69–74. doi:10.1016/j.mce.2007.09.006

    Article  CAS  PubMed  Google Scholar 

  28. Kvols L, Oberg KE, O’Dorisio T, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B (2012) Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study. Endocr Relat Cancer. doi:10.1530/ERC-11-0367

  29. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Unterhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, Arnold CN (2005) Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3:761–771

    Article  CAS  PubMed  Google Scholar 

  30. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61:6–32. doi:10.1136/gutjnl-2011-300831

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW (1968) Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2:895–898

    Article  CAS  PubMed  Google Scholar 

  32. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194. doi:10.1056/NEJM198011203032101

    Article  CAS  PubMed  Google Scholar 

  33. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523. doi:10.1056/NEJM199202203260804

    Article  CAS  PubMed  Google Scholar 

  34. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771. doi:10.1200/JCO.2004.04.024

    Article  CAS  PubMed  Google Scholar 

  35. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65:1883–1890

    Article  CAS  PubMed  Google Scholar 

  36. Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944–948. doi:10.1002/(SICI)1097-0142(19990915)86:6<944:AID-CNCR8>3.0.CO;2-P

    Article  CAS  PubMed  Google Scholar 

  37. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255–1259

    CAS  PubMed  Google Scholar 

  38. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, Costanzi JH (1987) A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60:2891–2895

    Article  CAS  PubMed  Google Scholar 

  39. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897–4904. doi:10.1200/JCO.2005.03.616

    Article  CAS  PubMed  Google Scholar 

  40. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406. doi:10.1200/JCO.2005.03.6046

    Article  CAS  PubMed  Google Scholar 

  41. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS (2006) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. ASCO Meeting Abstracts 24:4044

  42. Varker KA, Campbell J, Shah MH (2008) Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61:661–668

    Article  CAS  PubMed  Google Scholar 

  43. Ekeblad S, Sundin A, Janson E et al (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986–2991

    Article  CAS  PubMed  Google Scholar 

  44. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275. doi:10.1002/cncr.25425

    Article  CAS  PubMed  Google Scholar 

  45. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232

    Article  CAS  PubMed  Google Scholar 

  46. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102:1106–1112. doi:10.1038/sj.bjc.6605618

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund PJ, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri L-M, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2012) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal poorly differentiated neuroendocrine carcinoma: the NORDIC NEC study. ASCO Meeting Abstracts 30:4015

  48. Proye C (2001) Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 25:685–688

    Article  CAS  PubMed  Google Scholar 

  49. Maithel SK, Fong Y (2009) Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 100:635–638. doi:10.1002/jso.21196

    Article  PubMed  Google Scholar 

  50. Stippel DL, Brochhagen HG, Arenja M, Hunkemoller J, Holscher AH, Beckurts KT (2004) Variability of size and shape of necrosis induced by radiofrequency ablation in human livers: a volumetric evaluation. Ann Surg Oncol 11:420–425. doi:10.1245/ASO.2004.09.012

    Article  PubMed  Google Scholar 

  51. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, Gazelle GS (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214:761–768

    Article  CAS  PubMed  Google Scholar 

  52. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210:655–661

    Article  CAS  PubMed  Google Scholar 

  53. Livraghi T, Goldberg SN, Monti F, Bizzini A, Lazzaroni S, Meloni F, Pellicano S, Solbiati L, Gazelle GS (1997) Saline-enhanced radio-frequency tissue ablation in the treatment of liver metastases. Radiology 202:205–210

    Article  CAS  PubMed  Google Scholar 

  54. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A (1997) Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 122:1147–1154; discussion 1154–1145

  55. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602. doi:10.1002/cncr.21389

    Article  PubMed  Google Scholar 

  56. Norton JA, Kerlan RK (2003) Hepatic artery embolization for treatment of patients with metastatic carcinoid tumors: a commentary. Cancer J 9:241–243

    Article  PubMed  Google Scholar 

  57. Liu DM, Kennedy A, Turner D, Rose SC, Kee ST, Whiting S, Murthy R, Nutting C, Heran M, Lewandowski R, Knight J, Gulec S, Salem R (2009) Minimally invasive techniques in management of hepatic neuroendocrine metastatic disease. Am J Clin Oncol 32:200–215. doi:10.1097/COC.0b013e318172b3b6

    Article  CAS  PubMed  Google Scholar 

  58. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9:261–267

    Article  PubMed  Google Scholar 

  59. Strosberg JR, Choi J, Cantor AB, Kvols LK (2006) Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13:72–78

    PubMed  Google Scholar 

  60. Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S (2003) Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. Am J Roentgenol 180:1379–1384

    Article  Google Scholar 

  61. Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B, Guy G, Khabiri H, Ellison EC, Shah MH (2007) Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 11:264–271. doi:10.1007/s11605-007-0089-z

    Article  PubMed  Google Scholar 

  62. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513. doi:10.1056/NEJMoa1003825

    Article  CAS  PubMed  Google Scholar 

  63. Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK (2012) A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. doi:10.1093/annonc/mdr614

  64. Perry LJ, Stuart K, Stokes KR, Clouse ME (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116:1111–1116; discussion 1116–1117

  65. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine-related tumours with radioiodinated analog of somatostatin. Lancet 1:242–244

    Article  CAS  PubMed  Google Scholar 

  66. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 43:610–616

    CAS  PubMed  Google Scholar 

  67. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389–427

    Article  CAS  PubMed  Google Scholar 

  68. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130. doi:10.1200/JCO.2007.15.2553

    Article  CAS  PubMed  Google Scholar 

  69. Teunissen JJ, Kwekkeboom DJ, Krenning EP (2004) Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 22:2724–2729. doi:10.1200/JCO.2004.10.016

    Article  CAS  PubMed  Google Scholar 

  70. Kong G, Lau E, Ramdave S, Hicks RJ (2005) High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors. J Nucl Med 46(Suppl 2):151P

    Google Scholar 

  71. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32:110–122

    Article  PubMed  Google Scholar 

  72. van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ (2008) Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 35:743–748. doi:10.1007/s00259-007-0688-7

    Article  PubMed Central  PubMed  Google Scholar 

  73. Capdevila J, Salazar R (2009) Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Target Oncol 4:287–296. doi:10.1007/s11523-009-0128-7

    Article  PubMed  Google Scholar 

  74. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    CAS  PubMed  Google Scholar 

  75. O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605. doi:10.1182/blood-2002-07-2307

    Article  PubMed  Google Scholar 

  76. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745. doi:10.1038/nrd2380

    Article  CAS  PubMed  Google Scholar 

  77. Sablin MP, Dreyer C, Colichi C, Bouattour M, Delbaldo C, Faivre S, Raymond E (2010) Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. Expert Opin Drug Metab Toxicol 6:1005–1015. doi:10.1517/17425255.2010.506872

    Article  CAS  PubMed  Google Scholar 

  78. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403–3410. doi:10.1200/JCO.2007.15.9020

    Article  CAS  PubMed  Google Scholar 

  79. Vinik A, Van Cutsem E, Niccoli P, Raoul J-L, Bang Y-J, Borbath I, Valle JW, Metrakos P, Smith D, Chen J-S, Hoersch D, Castellano DE, Kennecke HF, Picus J, Van Hazel G, Patyna S, Lu D, Chao RC, Raymond E (2012) Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). ASCO Meeting Abstracts 30:4118

  80. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109. doi:10.1158/0008-5472.CAN-04-1443

    Article  CAS  PubMed  Google Scholar 

  81. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C (2007) MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J Clin Oncol (Meeting Abstracts) 25:4504

    Article  Google Scholar 

  82. Castellano D, Capdevilla J, Salazar R, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Abad A, Sevilla I, Duran I (2010) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of Spanish Neuroendocrine Tumor Group (GETNE-0801). 35th European Society of Medical Oncology 21:850P

  83. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13:1845–1857

    Article  CAS  PubMed  Google Scholar 

  84. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316–1323. doi:10.1200/JCO.2007.13.6374

    Article  CAS  PubMed  Google Scholar 

  85. Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, Leary C, Hess KR (2010) Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol (Meeting Abstracts) 28:4002

  86. Kunz PL, Kuo T, Zahn JM, Kaiser HL, Norton JA, Visser BC, Longacre TA, Ford JM, Balise RR, Fisher GA (2010) A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol (Meeting Abstracts) 28:4104

    Google Scholar 

  87. O’Donnell A, Faivre S, Burris HA III, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595. doi:10.1200/JCO.2007.14.0988

    Article  PubMed  Google Scholar 

  88. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors TTSG (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523. doi:10.1056/NEJMoa1009290

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012. doi:10.1016/S0140-6736(11)61742-X

    Article  CAS  PubMed  Google Scholar 

  90. Blumberg J, Gomez-Panzani E, Latapie-Martínez S, Liyanage S Somatuline® Autogel® 120 mg (lanreotide) Evaluation of Tumor Progression-Free Survival in patients with non-functioning entero-pancreatic endocrine tumors: an ongoing, double-blind, randomized, placebo-controlled, multicenter study (the CLARINET Study). In: 2010 Neuroendocrine Tumor Symposium, 2010. NANETS

  91. Pavel ME, Baum U, Hahn EG, Hensen J (2005) Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 35:179–185. doi:10.1385/IJGC:35:3:179

    Article  CAS  PubMed  Google Scholar 

  92. Kolby L, Persson G, Franzen S, Ahren B (2003) Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687–693. doi:10.1002/bjs.4149

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors acknowledge the financial support of Pfizer to maintain the necessary meetings to elaborate the contents of this manuscript and the medical writing services of Fernando Sánchez Barbero from HealthCo SL (Madrid, Spain).

Conflict of interest

The authors declare that they do not have any conflicts of interest that could inappropriately influence their work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel Castellano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castellano, D., Grande, E., Valle, J. et al. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemother Pharmacol 75, 1099–1114 (2015). https://doi.org/10.1007/s00280-014-2642-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2642-2

Keywords

Navigation